Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 nov. 2025 08h00 HE | Source: Adlai Nortye Ltd.

Adlai Nortye to Participate in Upcoming Investor Conferences

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...
22 oct. 2025 00h00 HE | Source: Adlai Nortye Ltd.

Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...
13 oct. 2025 23h07 HE | Source: Adlai Nortye Ltd.

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...
10 avr. 2025 08h00 HE | Source: Adlai Nortye Ltd.

Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...
08 août 2024 08h30 HE | Source: Adlai Nortye Ltd.

Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology...
08 août 2024 08h00 HE | Source: Adlai Nortye Ltd.

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology...
23 mai 2024 21h03 HE | Source: Adlai Nortye Ltd.

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology...
22 mai 2024 08h00 HE | Source: Adlai Nortye Ltd.

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...
29 mars 2024 06h00 HE | Source: Adlai Nortye Ltd.

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage...
17 nov. 2023 07h30 HE | Source: Adlai Nortye Ltd.

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology...

Page suivante